The Lancet Haematology

The Lancet Haematology is a world-leading #haematology journal publishing peer-reviewed research and reviews, opinion, and news. #hematology

[The Lancet Haematology @TheLancetHaem]

Women have unique presentations and consequences of haematological disorders, including anaemia, undiagnosed and undertreated bleeding disorders, and hormone-related thrombosis and bleeding. A new @TheLancetHaem Commission addresses these issues:
https://t.co/6A48VYo4Ke
1/6

[ISTH @isth]

🎙️ New ISTH Pulse Podcast! Join host Julia Sandrin Gauer with guests Bethany Samuelson-Bannow, Lan-Lan Smith and Maureen Achebe as they discuss the findings and recommendations from @TheLancetHaem Commission on Global Female Health and Haematology, released during #ISTH2026:

[The Lancet Haematology @TheLancetHaem]

If you are attending #ISTH2026 there are a few remaining print copies of our commission available at the ISTH hub. Also available online https://t.co/IzQCTFalFz

[ISTH @isth]

A landmark moment for women's health at #ISTH2026! @TheLancetHaem has published the Commission on Global Female Health and Haematology, a groundbreaking international collaboration focused on improving hematologic health for women and girls.

Learn more: https://t.co/PKwxiSHDOF

[ISTH @isth]

Today at #ISTH2026, the @TheLancetHaem Commission brought women’s health to the center stage! Learn more https://t.co/oWKIDpYA2R

[The Lancet Haematology @TheLancetHaem]

Explore the full Commission and related articles here: https://t.co/6A48VYo4Ke

6/6

[The Lancet Haematology @TheLancetHaem]

Women have unique presentations and consequences of haematological disorders, including anaemia, undiagnosed and undertreated bleeding disorders, and hormone-related thrombosis and bleeding. A new @TheLancetHaem Commission addresses these issues:
https://t.co/6A48VYo4Ke
1/6

[The Lancet Haematology @TheLancetHaem]

To address these many issues, the Commission sets out ten recommendations for regulators, international health bodies, professional societies, funders, and governments.

5/6

[The Lancet Haematology @TheLancetHaem]

Dr Stubblefield presents analysis from the RIETE registry showing an increase in use of unfractionated heparin to treat pts with acute pulmonary embolism #ISTH2026 what is used widely linked with geography.

[The Lancet Haematology @TheLancetHaem]

Read the full results of the METRO trial on mesoglycan for SVT presented by Prof Camporese at #ISTH2026 here:
https://t.co/AnUMbMOqlC

[The Lancet Haematology @TheLancetHaem]

Dr Bram Akerboom presented results from a trail showing the YEARS algorithm has improved safety but same efficacy for ruling out PE in pts with cancer compared with CTPA #ISTH2026

[The Lancet Haematology @TheLancetHaem]

Really nice talk from Prof Young-Hoon Jeong about the importance of consideration in antithrombotic strategy. #ISTH2026

[The Lancet Haematology @TheLancetHaem]

👀Watch this space for our next @TheLancetHaem Commission on reducing mortality, improving outcomes, and establishing equity for women with classical haematological disease lauching on Monday 13th July at 8 am CEST at #ISTH2026

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell #lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial #lymsm https://t.co/GhXUUvJ3Ek

[The Lancet Haematology @TheLancetHaem]

🩸July issue!

Epcoritamab for DLBCL; inotuzumab ozogamicin for paediatric B-cell ALL; patient-reported AEs after CAR T-cells for B-cell lymphomas; apixaban for paediatric VTEs.

Cover: classical haem service

🎙️https://t.co/zOBsDL9dlC

Issue here: https://t.co/dkrN9laf8r

[The Lancet Haematology @TheLancetHaem]

🏥Although 7 months elapsed between lymph node and skin involvement, mutational profiles were consistent with recurrent AITL alterations; the final diagnosis was cutaneous progression of AITL with secondary EBV-positive DLBCL.

Read it here: https://t.co/xBikxgkoI2
3/3

[The Lancet Haematology @TheLancetHaem]

📊Quiz Results Are In!

What is the diagnosis?

1⃣Mycosis fungoides 10.9%
2⃣Extranodal diffuse large B-cell lymphoma 51.9%✅
3⃣Panniculitis-like T-cell lymphoma 15.5%
4⃣Primary cutaneous follicle centre lymphoma 21.7%

1/3

[The Lancet Haematology @TheLancetHaem]

🧠Quiz Time!

An 83-year-old woman with stage IV angioimmunoblastic T-cell lymphoma developed a painful and pruritic rash on her face, chest, and back after 4 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).

1/3

[The Lancet Haematology @TheLancetHaem]

🩺More than 50% of cells were EBER-positive, with confluent sheets in the epidermis and mid-dermis; a type II latency pattern was identified, consistent with EBV-positive DLBCL.

2/3